Back

Quality Control Metrics for Whole Blood Transcriptome Analysis in the Parkinson's Progression Markers Initiative (PPMI)

Hutchins, E.; Craig, D. W.; Violich, I.; Alsop, E.; Casey, B.; Hutten, S.; Reimer, A.; Whitsett, T. G.; Crawford, K. L.; Toga, A. W.; Levy, S.; Robison, M.; Prasad, N.; Gibbs, J. R.; Cookson, M. R.; Parkinson's Progression Markers Initiative, ; Van Keuren-Jensen, K.

2021-01-08 genetic and genomic medicine
10.1101/2021.01.05.21249278 medRxiv
Show abstract

The Michael J. Fox Foundations Parkinsons Progression Markers Initiative (PPMI) is an observational study to comprehensively evaluate Parkinsons disease (PD) patients using imaging, biologic sampling, clinical and behavioural assessments to identify biomarkers of PD progression. As part of this study, we obtained 4,756 whole blood samples from 1,570 subjects at baseline, 0.5, 1, 2, and 3 years from enrollment in the study. We isolated RNA and performed whole transcriptome sequencing in this longitudinal cohort. Here, we describe and quantify technical variability associated with this dataset through the use of pooled reference samples, including plate distribution, RNA quality, and outliers. This large, uniformly processed dataset is available to researchers at https://www.ppmi-info.org.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.